Morphosys Ag (MOR) has released an update.
Novartis BidCo Germany AG plans to merge with MorphoSys AG, aiming for a merger squeeze-out to acquire the shares of MorphoSys’s minority shareholders. Novartis, already holding 91.04% of MorphoSys’s share capital, proposes negotiations for a merger agreement, with the intent to offer cash compensation yet to be determined. The proposed squeeze-out will be subject to the approval of MorphoSys AG shareholders at the upcoming Annual General Meeting in August 2024.
For further insights into MOR stock, check out TipRanks’ Stock Analysis page.
